Evaluation of cannabidiol nanoparticles and nanoemulsion biodistribution in the central nervous system after intrathecal administration for the treatment of pain

• DOI: 10.1016/j.nano.2023.102664
• Publication Date: 2023-02-20T18:07:47Z
• Authors: Paula Muresan; Stephen Woodhams; Fiona Smith; Vincenzo Taresco; Jaymin Shah; Mei Wong; Victoria Chapman; Stuart Smith; Gareth Hathway; Ruman Rahman; Pavel Gershkovich; Maria Marlow
• Keywords: 0303 health sciences; 03 medical and health sciences; Humans; Cannabidiol; Pain; Brain; Nanoparticles; Administration, Oral; Tissue Distribution; 3. Good health

We investigated how the biodistribution of cannabidiol (CBD) within the central nervous system (CNS) is influenced by two different formulations, an oil-in-water (O/W) nanoemulsion and polymer-coated nanoparticles (PCNPs). We observed that both CBD formulations administered were preferentially retained in the spinal cord, with high concentrations reaching the brain within 10 min of administration. The CBD nanoemulsion reached Cmax in the brain at 210 ng/g within 120 min (Tmax), whereas the CBD PCNPs had a Cmax of 94 ng/g at 30 min (Tmax), indicating that rapid brain delivery can be achieved through the use of PCNPs. Moreover, the AUC0-4h of CBD in the brain was increased 3.7-fold through the delivery of the nanoemulsion as opposed to the PCNPs, indicating higher retention of CBD at this site. Both formulations exhibited immediate anti-nociceptive effects in comparison to the respective blank formulations.